MedTrace Logo

Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease

NCT01189084 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 14

Last updated 2011-07-13

No results posted yet for this study

Summary

The purpose of this observational study is to determine whether the vaccine (UB 311), targeting the N-terminal amino acids (1-14) of the amyloid beta peptide, has long-term immunogenicity and efficacy in individuals diagnosed with mild or moderate Alzheimer's disease (AD) who previously received UB 311-treatment. Amyloid beta was selected as the target antigen based on supporting evidence of the hypothesis that places the accumulation of amyloid beta at the initiating step of AD.

Conditions

Interventions

BIOLOGICAL

Observational

Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).

Sponsors & Collaborators

  • Taipei Veterans General Hospital, Taiwan

    collaborator OTHER_GOV

  • National Taiwan University Hospital

    collaborator OTHER

  • United Biomedical

    lead INDUSTRY

Principal Investigators

  • Pei-Ning Wang, M.D. · Taipei Veterans General Hospital (TVGH)

  • Ming-Jang Chiu, M.D. · National Taiwan University Hospital (NTUH)

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Completion
2011-07-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01189084 on ClinicalTrials.gov